Imran Talat 4

Accession 0000950170-23-071472

CIK 0001856725other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:05 PM ET

Size

20.9 KB

Accession

0000950170-23-071472

Form 4

Period: 2023-12-16

DirectorChief Executive Officer

Transactions

Award
Stock Option (Right to Buy)
2023-12-16+479,667→ 479,667 total
Exercise: $2.84Exp: 2033-03-26→ Class A Common Stock (479,667 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−271,875→ 453,125 total
Exercise: $19.56Exp: 2031-09-08→ Class A Common Stock (271,875 underlying)
Award
271875
2023-12-16+271,875→ 271,875 total
Exercise: $2.84Exp: 2031-09-08→ Class A Common Stock (271,875 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−479,667→ 95,933 total
Exercise: $5.44Exp: 2033-03-26→ Class A Common Stock (479,667 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−153,650→ 109,750 total
Exercise: $13.21Exp: 2032-03-21→ Class A Common Stock (153,650 underlying)
Award
Stock Option (Right to Buy)
2023-12-16+153,650→ 153,650 total
Exercise: $2.84Exp: 2032-03-21→ Class A Common Stock (153,650 underlying)
Award
Stock Option (Right to Buy)
2023-12-16+31,252→ 31,252 total
Exercise: $2.84Exp: 2031-07-28→ Class A Common Stock (31,252 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−31,252→ 47,699 total
Exercise: $9.44Exp: 2031-07-28→ Class A Common Stock (31,252 underlying)

Footnotes (6)

[F1]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
[F2]The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
[F3]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
[F4]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
[F5]The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
[F6]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.

Documents

1 file

Rani Therapeutics Holdings, Inc.

CIK 0001856725

Entity typeother